MERTK inhibition selectively activates a DC - T-cell axis to provide anti-leukemia immunity.

Autor: Huelse JM; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta and Department of Pediatrics, Emory University, Atlanta, GA, 30322, USA., Bhasin SS; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta and Department of Pediatrics, Emory University, Atlanta, GA, 30322, USA., Jacobsen KM; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta and Department of Pediatrics, Emory University, Atlanta, GA, 30322, USA., Yim J; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta and Department of Pediatrics, Emory University, Atlanta, GA, 30322, USA., Thomas BE; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta and Department of Pediatrics, Emory University, Atlanta, GA, 30322, USA., Branella GM; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta and Department of Pediatrics, Emory University, Atlanta, GA, 30322, USA., Bakhtiari M; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta and Department of Pediatrics, Emory University, Atlanta, GA, 30322, USA., Chimenti ML; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta and Department of Pediatrics, Emory University, Atlanta, GA, 30322, USA., Baxter TA; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta and Department of Pediatrics, Emory University, Atlanta, GA, 30322, USA., Raikar SS; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta and Department of Pediatrics, Emory University, Atlanta, GA, 30322, USA., Wang X; Center for Integrative Chemical Biology and Drug Discovery and Division of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.; UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC, 27599, USA., Frye SV; Center for Integrative Chemical Biology and Drug Discovery and Division of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.; UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC, 27599, USA., Henry CJ; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta and Department of Pediatrics, Emory University, Atlanta, GA, 30322, USA.; Department of Immunology and Microbiology, The University of Colorado Anschutz Medical Campus, Aurora, CO, 80045, USA., Earp HS; UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC, 27599, USA.; Departments of Medicine and Pharmacology, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA., Bhasin M; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta and Department of Pediatrics, Emory University, Atlanta, GA, 30322, USA.; Cancer Immunology Program, Winship Cancer Institute, Emory University, Atlanta, GA, 30322, USA.; Wallace H Coulter Department of Biomedical Engineering, Emory University and Georgia Tech, Atlanta, GA, 30322, USA., DeRyckere D; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta and Department of Pediatrics, Emory University, Atlanta, GA, 30322, USA., Graham DK; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta and Department of Pediatrics, Emory University, Atlanta, GA, 30322, USA. douglas.graham@choa.org.

Publikováno v: Leukemia [Leukemia] 2024 Dec; Vol. 38 (12), pp. 2685-2698. Date of Electronic Publication: 2024 Sep 25.

Linger RMA, DeRyckere D, Brandão L, Sawczyn KK, Jacobsen KM, Liang X, Keating AK, Graham DK. Mer receptor tyrosine kinase is a novel therapeutic target in pediatric B-cell acute lymphoblastic leukemia. Blood. 2009;114(13):2678–2687

Acute lymphoblastic leukemia (ALL) is currently treated with an intense regimen of chemotherapy yielding cure rates near 80%. However, additional changes using available drugs are unlikely to provide significant improvement in survival. New therapies

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::4d30f813969491401924f18f8c5dcbef
https://europepmc.org/articles/PMC3490099/

Linger RMA, DeRyckere D, Brandão L, Sawczyn KK, Jacobsen KM, Liang X, Keating AK, Graham DK. Mer receptor tyrosine kinase is a novel therapeutic target in pediatric B-cell acute lymphoblastic leukemia. Blood. 2009;114(13):2678–2687.

Publikováno v: In Blood 16 August 2012 120(7):1533-1533

Constitutively Synergistic Multiagent Drug Formulations Targeting MERTK, FLT3, and BCL-2 for Treatment of AML.

Autor: Kelvin JM; Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, GA, 30322, USA., Jain J; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, 30322, USA.; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, GA, 30322, USA.; Department of Pediatrics, University of Arizona College of Medicine, and Banner University Medical Center Tucson, Tucson, AZ, 85724, USA., Thapa A; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, 30322, USA., Qui M; Department of Pharmacology and Chemical Biology, Emory Chemical Biology Discovery Center, Emory University School of Medicine, Atlanta, GA, 30322, USA., Birnbaum LA; Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, GA, 30322, USA., Moore SG; Systems Mass Spectrometry Core Facility, Georgia Institute of Technology, Atlanta, GA, 30332, USA., Zecca H; Department of Chemistry, Emory University, Atlanta, GA, 30322, USA., Summers RJ; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, 30322, USA.; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, GA, 30322, USA., Switchenko JM; Department of Biostatistics and Bioinformatics, Rollins School of Public Health, Emory University, Atlanta, GA, 30322, USA.; Winship Cancer Institute of Emory University, Atlanta, GA, 30322, USA., Costanza E; Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, GA, 30322, USA., Uricoli B; Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, GA, 30322, USA., Wang X; Center for Integrative Chemical Biology and Drug Discovery, Division of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA., Jui NT; Department of Chemistry, Emory University, Atlanta, GA, 30322, USA.; Petit Institute for Bioengineering and Bioscience, Georgia Institute of Technology, Atlanta, GA, 30332, USA., Fu H; Department of Pharmacology and Chemical Biology, Emory Chemical Biology Discovery Center, Emory University School of Medicine, Atlanta, GA, 30322, USA.; Winship Cancer Institute of Emory University, Atlanta, GA, 30322, USA., Du Y; Department of Pharmacology and Chemical Biology, Emory Chemical Biology Discovery Center, Emory University School of Medicine, Atlanta, GA, 30322, USA.; Winship Cancer Institute of Emory University, Atlanta, GA, 30322, USA., DeRyckere D; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, 30322, USA.; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, GA, 30322, USA., Graham DK; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, 30322, USA. Douglas.Graham@choa.org.; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, GA, 30322, USA. Douglas.Graham@choa.org., Dreaden EC; Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, GA, 30322, USA. e.dreaden@emory.edu.; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, 30322, USA. e.dreaden@emory.edu.; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, GA, 30322, USA. e.dreaden@emory.edu.; Winship Cancer Institute of Emory University, Atlanta, GA, 30322, USA. e.dreaden@emory.edu.; Petit Institute for Bioengineering and Bioscience, Georgia Institute of Technology, Atlanta, GA, 30332, USA. e.dreaden@emory.edu.

Publikováno v: Pharmaceutical research [Pharm Res] 2023 Sep; Vol. 40 (9), pp. 2133-2146. Date of Electronic Publication: 2023 Sep 13.

Single-cell RNA sequencing distinctly characterizes the wide heterogeneity in pediatric mixed phenotype acute leukemia.

Autor: Mumme HL; Aflac Cancer and Blood Disorders Center, Children Healthcare of Atlanta, Atlanta, GA, USA.; Department of Biomedical Informatics, Emory University, Atlanta, GA, USA., Raikar SS; Aflac Cancer and Blood Disorders Center, Children Healthcare of Atlanta, Atlanta, GA, USA.; Department of Pediatrics, Emory University, Atlanta, GA, USA., Bhasin SS; Aflac Cancer and Blood Disorders Center, Children Healthcare of Atlanta, Atlanta, GA, USA.; Department of Pediatrics, Emory University, Atlanta, GA, USA., Thomas BE; Aflac Cancer and Blood Disorders Center, Children Healthcare of Atlanta, Atlanta, GA, USA.; Department of Pediatrics, Emory University, Atlanta, GA, USA., Lawrence T; Aflac Cancer and Blood Disorders Center, Children Healthcare of Atlanta, Atlanta, GA, USA., Weinzierl EP; Department of Pathology and Laboratory Medicine, Children's Healthcare of Atlanta, Atlanta, GA, USA., Pang Y; Department: Pediatrics - Hematology/Oncology, Stanford University, Stanford, CA, USA., DeRyckere D; Aflac Cancer and Blood Disorders Center, Children Healthcare of Atlanta, Atlanta, GA, USA.; Department of Pediatrics, Emory University, Atlanta, GA, USA., Gawad C; Department: Pediatrics - Hematology/Oncology, Stanford University, Stanford, CA, USA., Wechsler DS; Aflac Cancer and Blood Disorders Center, Children Healthcare of Atlanta, Atlanta, GA, USA.; Department of Pediatrics, Emory University, Atlanta, GA, USA., Porter CC; Aflac Cancer and Blood Disorders Center, Children Healthcare of Atlanta, Atlanta, GA, USA.; Department of Pediatrics, Emory University, Atlanta, GA, USA., Castellino SM; Aflac Cancer and Blood Disorders Center, Children Healthcare of Atlanta, Atlanta, GA, USA.; Department of Pediatrics, Emory University, Atlanta, GA, USA., Graham DK; Aflac Cancer and Blood Disorders Center, Children Healthcare of Atlanta, Atlanta, GA, USA.; Department of Pediatrics, Emory University, Atlanta, GA, USA., Bhasin M; Aflac Cancer and Blood Disorders Center, Children Healthcare of Atlanta, Atlanta, GA, USA. manoj.bhasin@emory.edu.; Department of Biomedical Informatics, Emory University, Atlanta, GA, USA. manoj.bhasin@emory.edu.; Department of Pediatrics, Emory University, Atlanta, GA, USA. manoj.bhasin@emory.edu.

Publikováno v: Genome medicine [Genome Med] 2023 Oct 16; Vol. 15 (1), pp. 83. Date of Electronic Publication: 2023 Oct 16.